mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 3155-3161

  Bache, Matthias ^a   Rot, Swetlana ^a   Kessler, Jacqueline ^a   Güttler, Antje ^a   Wichmann, Henri ^a   Greither, Thomas ^a   Wach, Sven ^b   Taubert, Helge ^b   Söling, Ariane ^c   Bilkenroth, Udo ^d   Kappler, Matthias ^a   Vordermark, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Institute of Pathology   (Germany)

Author keywords

Glioblastoma; Hypoxia induced and stem cell associated genes; mRNA expression

Indexed keywords

CARBONATE DEHYDRATASE IX; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE TRANSPORTER 1; HYDROXYUREA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOPONTIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR NANOG; VASCULOTROPIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; SLC2A1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER RADIOTHERAPY; CELL HYPOXIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARBONIC ANHYDRASES; CELL HYPOXIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUCOSE TRANSPORTER TYPE 1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OSTEOPONTIN; PROGNOSIS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84928901792     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3932     Document Type: Article

References (50)

1. Henriksson R, Asklund T and Poulsen HS: Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104: 639-646, 2011.
2. Nieder C and Mehta MP: Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Med Hypotheses 76: 410-413, 2011.
3. Shirai K and Chakravarti A: Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther 11: 1935-1944, 2011.
4. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
5. Bristow RG and Hill RP: Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180-192, 2008.
6. Collingridge DR, Piepmeier JM, Rockwell S and Knisely JP: Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 53: 127-131, 1999.
7. Bar EE: Glioblastoma, cancer stem cells and hypoxia. Brain Pathol 21: 119-129, 2011.
8. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB and Rich JN: The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8: 3274-3284, 2009.
9. McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K and Tofilon PJ: Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7: 489-497, 2009.
10. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schänzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nistér M, et al: A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133: 983-995, 2010.
11. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brünner N and Kristensen BW: Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 103: 43-58, 2011.
12. Vordermark D and Brown JM: Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 179: 801-811, 2003.
13. Bache M, Kappler M, Said HM, Staab A and Vordermark D: Detection and specific targeting of hypoxic regions within solid tumors: Current preclinical and clinical strategies. Curr Med Chem 15: 322-338, 2008.
14. Dahlrot RH, Hermansen SK, Hansen S and Kristensen BW: What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol 6: 334-348, 2013.
15. Haar CP, Hebbar P, Wallace GC IV, Das A, Vandergrift WA III, Smith JA, Giglio P, Patel SJ, Ray SK and Banik NL: Drug resistance in glioblastoma: a mini review. Neurochem Res 37: 1192-1200, 2012.
16. Tanaka S, Louis DN, Curry WT, Batchelor TT and Dietrich J: Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 10: 14-26, 2013.
17. Dreyfuss JM, Johnson MD and Park PJ: Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 8: 71, 2009.
18. Jin F, Zhao L, Zhao HY, Guo SG, Feng J, Jiang XB, Zhang SL, Wei YJ, Fu R and Zhao JS: Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience 154: 541-550, 2008.
19. Casalbore P, Budoni M, Ricci-Vitiani L, Cenciarelli C, Petrucci G, Milazzo L, Montano N, Tabolacci E, Maira G, Larocca LM, et al: Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1. PLoS One 4: e4434, 2009.
20. Acquati S, Greco A, Licastro D, Bhagat H, Ceric D, Rossini Z, Grieve J, Shaked-Rabi M, Henriquez NV, Brandner S, et al: Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells 31: 190-202, 2013.
21. Guvenc H, Pavlyukov MS, Joshi K, Kurt H, Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Bhasin D, et al: Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 19: 631-642, 2013.
22. Mao XG, Hütt-Cabezas M, Orr BA, Weingart M, Taylor I, Rajan AK, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G, et al: LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget 4: 1050-1064, 2013.
23. Paul I, Bhattacharya S, Chatterjee A and Ghosh MK: Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk. Genes Cancer 4: 427-446, 2013.
24. Söling A, Plugge EM, Schmitz M, Weigle B, Jacob R, Illert J, Holzhausen HJ and Rainov NG: Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol 30: 123-128, 2007.
25. Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, et al: Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 10: 132, 2010.
26. Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K and Vordermark D: Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83: 398-405, 2007.
27. Søndergaard KL, Hilton DA, Penney M, Ollerenshaw M and Demaine AG: Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol 28: 210-217, 2002.
28. Zhou YH, Tan F, Hess KR and Yung WK: The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9: 3369-3375, 2003.
29. Nam DH, Park K, Suh YL and Kim JH: Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: Prognostic significance. Oncol Rep 11: 863-869, 2004.
30. Scrideli CA, Carlotti CG Jr, Mata JF, Neder L, Machado HR, Oba-Sinjo SM, Rosemberg S, Marie SK and Tone LG: Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas. J Neurooncol 83: 233-239, 2007.
31. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K and Kurisu K: Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97: 1077-1083, 2003.
32. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM and Held-Feindt J: Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 86: 31-45, 2008.
33. Sun G, Wang Y, Sun L, Luo H, Liu N, Fu Z and You Y: Clinical significance of Hiwi gene expression in gliomas. Brain Res 1373: 183-188, 2011.
34. Yoshimoto K, Ma X, Guan Y, Mizoguchi M, Nakamizo A, Amano T, Hata N, Kuga D and Sasaki T: Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. Brain Tumor Pathol 28: 291-296, 2011.
35. Wang L, He S, Yuan J, Mao X, Cao Y, Zong J, Tu Y and Zhang Y: Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol 29: 3484-3490, 2012.
36. Güttler A, Giebler M, Cuno P, Wichmann H, Kessler J, Ostheimer C, Söling A, Strauss C, Illert J, Kappler M, et al: Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy. Radiother Oncol 108: 535-540, 2013.
37. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, et al: Stem cell-related 'self-renewal' signature and high epidermal growth fact or receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024, 2008.
38. Feng R, Zhou S, Liu Y, Song D, Luan Z, Dai X, Li Y, Tang N, Wen J and Li L: Sox2 protects neural stem cells from apoptosis via up-regulating survivin expression. Biochem J 450: 459-468, 2013.
39. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M and Yang L: Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281: 25903-25914, 2006.
40. Misra A, Pandey C, Sze SK and Thanabalu T: Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). PLoS One 7: e49766, 2012.
41. Korkolopoulou P, Patsouris E, Konstantinidou AE, Pavlopoulos PM, Kavantzas N, Boviatsis E, Thymara I, Perdiki M, Thomas-Tsagli E, Angelidakis D, et al: Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30: 267-278, 2004.
42. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY and Jensen RL: Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 113: 1032-1042, 2008.
43. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE II, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ and Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26: 271-278, 2008.
44. Hofstetter CP, Burkhardt JK, Shin BJ, Gürsel DB, Mubita L, Gorrepati R, Brennan C, Holland EC and Boockvar JA: Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. PLoS One 7: e30059, 2012.
45. Proescholdt MA, Merrill MJ, Stoerr EM, Lohmeier A, Pohl F and Brawanski A: Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol 14: 1357-1366, 2012.
46. Erpolat OP, Gocun PU, Akmansu M, Ozgun G and Akyol G: Hypoxia-related molecules HIF-1α, CA9, and osteopontin: predictors of survival in patients with high-grade glioma. Strahlenther Onkol 189: 147-154, 2013.
47. 6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. Oncol Rep 26: 1305-1313, 2011.
48. Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, et al: Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol 18: 2937-2945, 2011.
49. Nakata S, Campos B, Bageritz J, Bermejo JL, Becker N, Engel F, Acker T, Momma S, Herold-Mende C, Lichter P, et al: LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol 23: 60-72, 2013.
50. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, et al: Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14: 8205-8212, 2008.